Chloramphenicol sodium succinate is a water-soluble prodrug of the broad-spectrum antibiotic chloramphenicol. It is formed by esterifying chloramphenicol with succinic acid, followed by conversion to its sodium salt. This modification significantly enhances its solubility in aqueous solutions, making it suitable for parenteral administration, particularly intravenous and intramuscular injection. Its primary and definitive application is as an active pharmaceutical ingredient (API) in human and veterinary medicine for the treatment of serious systemic infections caused by susceptible bacteria, including Salmonella typhi, Haemophilus influenzae, and certain rickettsiae. It is specifically indicated when oral administration is not feasible. The prodrug is rapidly hydrolyzed in vivo by esterases to release the active chloramphenicol. Due to the risk of serious adverse effects like bone marrow suppression and gray baby syndrome, its use is typically reserved for life-threatening infections where safer alternatives are ineffective or contraindicated. In pharmaceutical manufacturing, chloramphenicol sodium succinate also serves as a key synthetic building block or intermediate in the formulation of sterile injectable dosage forms. Its handling requires strict adherence to safety protocols due to its potent biological activity and potential health hazards.